Literature DB >> 25697710

Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.

Rebecca E H Whiting1, Jacqueline W Pearce2, Leilani J Castaner3, Cheryl A Jensen3, Rebecca J Katz4, Douglas H Gilliam5, Martin L Katz1.   

Abstract

The CLN2 form of neuronal ceroid lipofuscinosis is an autosomal recessively inherited lysosomal storage disease that is characterized by progressive vision loss culminating in blindness, cognitive and motor decline, neurodegeneration, and premature death. CLN2 disease results from mutations in the gene that encodes the soluble lysosomal enzyme tripeptidyl peptidase-1. A null mutation in the TPP1 gene encoding this enzyme causes a CLN2-like disease in Dachshunds. Dachshunds that are homozygous for this mutation serve as a model for human CLN2 disease, exhibiting clinical signs and neuropathology similar to those of children with this disorder. Affected dogs reach end-stage terminal disease status at 10-11 months of age. In addition to retinal changes typical of CLN2 disease, a retinopathy consisting of multifocal, bullous retinal detachment lesions was identified in 65% of (TPP1-/-) dogs in an established research colony. These lesions did not occur in littermates that were heterozygous or homozygous for the normal TPP1 allele. Retinal changes and the functional effects of this multifocal retinopathy were examined objectively over time using ophthalmic examinations, fundus photography, electroretinography (ERG), quantitative pupillary light response (PLR) recording, fluorescein angiography, optical coherence tomography (OCT) and histopathology. The retinopathy consisted of progressive multifocal serous retinal detachments. The severity of the disease-related retinal thinning was no more serious in most detached areas than in adjacent areas of the retina that remained in close apposition to the retinal pigment epithelium. The retinopathy observed in these dogs was somewhat similar to canine multifocal retinopathy (CMR), a disease caused by a mutation of the bestrophin gene BEST1. ERG a-wave amplitudes were relatively preserved in the Dachshunds with CLN2 disease, whether or not they developed the multifocal retinopathy. The retinopathy also had minimal effects on the PLR. Histological evaluation indicated that the CLN2 disease-related retinal degeneration was not exacerbated in areas where the retina was detached except where the detached areas were very large. DNA sequence analysis ruled out a mutation in the BEST1 exons or splice junctions as a cause for the retinopathy. Perfect concordance between the TPP1 mutation and the retinopathy in the large number of dogs examined indicates that the retinopathy most likely occurs as a direct result of the TPP1 mutation. Therefore, inhibition of the development and progression of these lesions can be used as an indicator of the efficacy of therapeutic interventions currently under investigation for the treatment of CLN2 disease in the Dachshund model. In addition, these findings suggest that TPP1 mutations may underlie multifocal retinopathies of unknown cause in animals and humans.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BEST1; Bullous retinopathy; CLN2; Canine; Dog; Neuronal ceroid lipofuscinosis; Retinal detachment; TPP1

Mesh:

Substances:

Year:  2015        PMID: 25697710      PMCID: PMC4426040          DOI: 10.1016/j.exer.2015.02.012

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  33 in total

Review 1.  Photoreceptor cell death and rescue in retinal detachment and degenerations.

Authors:  Yusuke Murakami; Shoji Notomi; Toshio Hisatomi; Toru Nakazawa; Tatsuro Ishibashi; Joan W Miller; Demetrios G Vavvas
Journal:  Prog Retin Eye Res       Date:  2013-08-28       Impact factor: 21.198

2.  A CLN8 nonsense mutation in the whole genome sequence of a mixed breed dog with neuronal ceroid lipofuscinosis and Australian Shepherd ancestry.

Authors:  Juyuan Guo; Gary S Johnson; Holly A Brown; Michele L Provencher; Ronaldo C da Costa; Tendai Mhlanga-Mutangadura; Jeremy F Taylor; Robert D Schnabel; Dennis P O'Brien; Martin L Katz
Journal:  Mol Genet Metab       Date:  2014-06-04       Impact factor: 4.797

3.  Canine multifocal retinopathy in the Australian Shepherd: a case report.

Authors:  Ingo Hoffmann; Karina E Guziewicz; Barbara Zangerl; Gustavo D Aguirre; Christian Y Mardin
Journal:  Vet Ophthalmol       Date:  2012-03-20       Impact factor: 1.644

Review 4.  The eclectroretinogram: its components and their origins.

Authors:  K T Brown
Journal:  Vision Res       Date:  1968-06       Impact factor: 1.886

Review 5.  Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses.

Authors:  Varun Warrier; Mariana Vieira; Sara E Mole
Journal:  Biochim Biophys Acta       Date:  2013-03-28

6.  Guidelines for clinical electroretinography in the dog: 2012 update.

Authors:  Björn Ekesten; András M Komáromy; Ron Ofri; Simon M Petersen-Jones; Kristina Narfström
Journal:  Doc Ophthalmol       Date:  2013-06-01       Impact factor: 2.379

7.  Pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Kristina Narfström; Gang Yao; Jacqueline W Pearce; Joan R Coates; Leilani J Castaner; Martin L Katz
Journal:  Exp Eye Res       Date:  2013-10-14       Impact factor: 3.467

8.  Mutations in IMPG1 cause vitelliform macular dystrophies.

Authors:  Gaël Manes; Isabelle Meunier; Almudena Avila-Fernández; Sandro Banfi; Guylène Le Meur; Xavier Zanlonghi; Marta Corton; Francesca Simonelli; Philippe Brabet; Gilles Labesse; Isabelle Audo; Saddek Mohand-Said; Christina Zeitz; José-Alain Sahel; Michel Weber; Hélène Dollfus; Claire-Marie Dhaenens; Delphine Allorge; Elfride De Baere; Robert K Koenekoop; Susanne Kohl; Frans P M Cremers; Joe G Hollyfield; Audrey Sénéchal; Maxime Hebrard; Béatrice Bocquet; Carmen Ayuso García; Christian P Hamel
Journal:  Am J Hum Genet       Date:  2013-08-29       Impact factor: 11.025

9.  A rare homozygous MFSD8 single-base-pair deletion and frameshift in the whole genome sequence of a Chinese Crested dog with neuronal ceroid lipofuscinosis.

Authors:  Juyuan Guo; Dennis P O'Brien; Tendai Mhlanga-Mutangadura; Natasha J Olby; Jeremy F Taylor; Robert D Schnabel; Martin L Katz; Gary S Johnson
Journal:  BMC Vet Res       Date:  2015-01-03       Impact factor: 2.741

10.  Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).

Authors:  Martin L Katz; Joan R Coates; Christine M Sibigtroth; Jacob D Taylor; Melissa Carpentier; Whitney M Young; Fred A Wininger; Derek Kennedy; Brian R Vuillemenot; Charles A O'Neill
Journal:  J Neurosci Res       Date:  2014-06-17       Impact factor: 4.164

View more
  10 in total

1.  Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Jacqueline W Pearce; Daniella P Vansteenkiste; Katherine Bibi; Stefanie Lim; Grace Robinson Kick; Leilani J Castaner; John Sinclair; Sundeep Chandra; Annalisa Nguyen; Charles A O'Neill; Martin L Katz
Journal:  Exp Eye Res       Date:  2020-07-01       Impact factor: 3.467

2.  Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Grace Robinson Kick; Juri Ota-Kuroki; Stefanie Lim; Leilani J Castaner; Cheryl A Jensen; Joseph Kowal; Annalisa Nguyen; Carley Corado; Charles A O'Neill; Martin L Katz
Journal:  Exp Eye Res       Date:  2020-07-04       Impact factor: 3.770

3.  Retinal Degeneration In A Mouse Model Of CLN5 Disease Is Associated With Compromised Autophagy.

Authors:  Henri Leinonen; Velta Keksa-Goldsteine; Symantas Ragauskas; Philip Kohlmann; Yajuvinder Singh; Ekaterina Savchenko; Jooseppi Puranen; Tarja Malm; Giedrius Kalesnykas; Jari Koistinaho; Heikki Tanila; Katja M Kanninen
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

Review 4.  Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.

Authors:  Kyeongsoon Kim; Hynda K Kleinman; Hahn-Jun Lee; Kalipada Pahan
Journal:  Orphanet J Rare Dis       Date:  2017-06-17       Impact factor: 4.123

5.  Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.

Authors:  M L Katz; G C Johnson; S B Leach; B G Williamson; J R Coates; R E H Whiting; D P Vansteenkiste; M S Whitney
Journal:  Gene Ther       Date:  2017-02-02       Impact factor: 5.250

6.  Changes in retinal layer thickness with maturation in the dog: an in vivo spectral domain - optical coherence tomography imaging study.

Authors:  Laurence M Occelli; Nate Pasmanter; Elias E Ayoub; Simon M Petersen-Jones
Journal:  BMC Vet Res       Date:  2020-06-30       Impact factor: 2.741

7.  Optical coherence tomography and molecular analysis of sudden acquired retinal degeneration syndrome (SARDS) eyes suggests the immune-mediated nature of retinal damage.

Authors:  Sinisa D Grozdanic; Tatjana Lazic; Helga Kecova; Kabhilan Mohan; Markus H Kuehn
Journal:  Vet Ophthalmol       Date:  2018-08-15       Impact factor: 1.644

8.  Natural history of retinal degeneration in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses.

Authors:  S J Murray; N L Mitchell
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

9.  Visual system pathology in a canine model of CLN5 neuronal ceroid lipofuscinosis.

Authors:  Grace Robinson Kick; Elizabeth J Meiman; Julianna C Sabol; Rebecca E H Whiting; Juri Ota-Kuroki; Leilani J Castaner; Cheryl A Jensen; Martin L Katz
Journal:  Exp Eye Res       Date:  2021-06-30       Impact factor: 3.770

10.  Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.

Authors:  Rebecca E H Whiting; Cheryl A Jensen; Jacqueline W Pearce; Lauren E Gillespie; Daniel E Bristow; Martin L Katz
Journal:  Exp Eye Res       Date:  2016-04-01       Impact factor: 3.467

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.